This website is intended for healthcare professionals only.
Take a look at a selection of our recent media coverage:
8th August 2023
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reinforced its emergency anaphylaxis guidance amid a doubling in hospitalisations in England over the last 20 years.
The most recent NHS England figures show 25,721 allergy-related hospital admissions in 2022/23 – an increase of 108% on the 12,361 admissions in 2002/03.
For food-related anaphylaxis and other adverse reactions, the rise was even higher, climbing from 1,971 admissions in 2002/03 to over 5,000 in 2022/23.
The MHRA issued new guidance in June on how to recognise and respond to the signs of anaphylaxis and on the use of adrenaline auto-injectors.
Now, the MHRA is encouraging people to download its advice in light of this new NHS admissions data as the steps, when taken immediately in response to anaphylaxis, can be the difference between life and death, it says.
MHRA chief officer for healthcare quality and access Laura Squire said the figures highlight ‘just how serious the consequences of allergies can be, and the rising numbers of hospitalisations highlights the need to know how to act in an emergency.‘
People at risk of anaphylaxis should always carry two auto-injectors and these should be regularly checked to ensure they have not expired.
In case of an anaphylaxis emergency patients should use their auto-injector without delay and immediately contact 999.
Patients should be made to lay down flat with their legs raised, or lay on their left side if they are pregnant. If there is no improvement after five minutes, a second auto-injector should be used.
Ms Squire added: ‘Knowing how to use an adrenaline auto-injector and what to do afterwards is crucial when responding in an emergency, whether you’re having the reaction yourself or helping someone else.
‘Anaphylaxis is scary for everyone involved and when it strikes, it’s not easy to remember what the right steps are. That’s why we want to encourage everyone to download our guidance now so they can be confident they’re doing the right thing if they’re ever in that situation.’
28th July 2021
According to the World Allergy Organization, the allergy prevalence among the whole population ranges from 10-40%. Moreover, the number people in the UK with allergies, appears to be increasing by 5% every year. One possible cause of the increased prevalence of allergic disease is childhood vaccination although the available evidence is inconsistent. Nevertheless, any perception that childhood vaccination might increase the risk for the development of allergic diseases jeopardises the attainment of herd immunity and the attendant risk of outbreaks of the particular vaccine-controlled infection disease.
With gaps in the current evidence, a team from the Faculty of Medicine, Department of Community Medicine, University of Peradeniya, Kandy, Sri Lanka, decided to undertake a systemic review and meta-analysis to examine the relationship between childhood vaccination and allergy. The team performed a search of the main databases such as PubMed and EMBASE for original studies examining exposure (in this case childhood vaccination) and allergic outcome.
They restricted the review to randomised controlled trials and prospective cohort studies although did not exclude any studies where there were differences in the timing, number of doses or if the comparators were placebo, controlled vaccine or even no vaccine. The exposure of interest was defined as any childhood vaccination and the primary outcomes of interest were asthma/wheeze, rhino conjunctivitis, allergic rhinitis, atopic eczema, food allergy and allergic sensitisation.
A total of 42 eligible studies were included in the analysis covering vaccination with BCG, pertussis, MMR and DTP. This comprised 35 cohort studies and 7 randomised controlled trials. In their analysis, the authors found that none of the randomised trials found any evidence of an association between BCG or pertussis and allergic manifestations. In fact, two randomised trials observed a reduction in the risk of developing eczema (Risk ratio, RR = 0.83, 95% CI 0.73–0.93) but not for food allergy or asthma.
Among cohort studies, childhood vaccination against measles was also associated with a reduced risk of eczema (RR = 0.65, 95% CI 0.47–0.90), asthma (RR = 0.78) and a non-significant reduction in allergic sensitisation (RR = 0.78, 95% CI 0.61–1.01). There was a trend towards a protective effect of measles vaccination against asthma (RR = 0.97), eczema (RR = 0.70) but a slight increased risk for allergy, though none of these associations were statistically significant.
In discussing their findings, the authors noted that there was no clear evidence that childhood vaccination was associated with an increased risk of allergic disease for the commonly given immunisations. In fact, if anything, the opposite was true, with the data suggesting a small, but potentially protective role against the development of eczema, particularly for measles. They concluded that while more studies are required to confirm these findings, it was important to promote the continuation of childhood vaccination to prevent the development of vaccine-preventable disease.
Navaratna S et al. Childhood vaccination and allergy: A systematic review and meta-analysis. Allergy 2021
27th November 2020
While the precise cause of CSU remains unclear, contemporary European guidelines advocate the use of second-generation antihistamines as a first-line treatment for the condition. Although these drugs can be effective, for patients in which symptom control remains inadequate, the guidance recommends up-dosing to four times the recommended dose as a second-line treatment option.
This latter commendation is based on expert opinion and for this study, a team from the Allergology Department, Complexo Hospital, A Coruna, Spain, set out to review the available evidence to support this approach. They included studies published in English or Spanish with patients at least 12 years of age with CSU on regular (as opposed to “on-demand”) therapy with a second-generation antihistamine. Other inclusion criteria were that the study should have a single antihistamine (rather than a combination), a placebo arm and using the drug at a higher than recommended dosage.
In total and after removal of duplicates and exclusions, only 14 articles were analysed in detail including 20 to 439 patients. Six studies focused on fexofenadine (up-dosing to 720 mg), 2 on cetirizine, levocetirizine, rupatadine, desloratadine and 1 trial with either ebastine or bilastine. Furthermore, only 5 of these trials were placebo controlled and all studies lasted between 2 and 8 weeks except for one fexofenadine trial which lasted 16 weeks. A higher dose of fexofenadine produced a dose-dependent significant response and controlled CSU in the majority of patients. Commenting on their findings, the authors noted that of the 14 trials, only 6 were of high quality and that the high level of heterogeneity in sample size, design, duration etc, which made it very difficult to make comparisons. Interestingly, they also note that despite current guideline recommendations, most studies did not find a significant impact on symptom control from up-dosing.
The authors concluded that while up-dosing appears both effective and safe, there is a lack of evidence to support this approach and called for further studies to validate the recommendations in guidelines.
Iriarte SP T et al. Up-dosing antihistamines inn chronic spontaneous urticaria: efficacy and safety. A systematic review of the literature. J Investig Allergol Clin Immunol 2020 doi: 10.18176/jiaci.0649